Real-World Effectiveness of Upadacitinib in Patients Joining Subgroups Either With Oligo- or Poly-ArtIcular Psoriatic Arthritis on Minimal Disease Activity
Latest Information Update: 24 Jul 2024
At a glance
- Drugs Upadacitinib (Primary)
- Indications Psoriatic arthritis
- Focus Therapeutic Use
- Acronyms UPJOINT
- Sponsors AbbVie
- 15 Jun 2024 Results (n=364) presented at the 25th Annual Congress of the European League Against Rheumatism
- 02 Nov 2023 Status changed from active, no longer recruiting to completed.
- 26 Apr 2023 Status changed from recruiting to active, no longer recruiting.